Vimseltinib improves outcomes in tenosynovial giant cell tumour

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-06-24 DOI:10.1038/s41571-024-00921-y

David Killock

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Vimseltinib可改善腱鞘巨细胞瘤的治疗效果

腱鞘巨细胞瘤（TGCT）是一种局部侵袭性肌腱肿瘤，无法始终通过手术治疗。TGCT由CSF1分泌失调和依赖CSF1R的炎性巨噬细胞驱动，CSF1R导向的多靶点酪氨酸激酶抑制剂（TKI）pexidartinib是FDA批准的治疗这种疾病的全身性药物，但可能导致潜在的致命性胆汁淤积性肝毒性。在MOTION试验中，123名不适合切除的TGCT患者被随机分配（2:1）接受每周两次的vimseltinib或安慰剂治疗，与之前的治疗（CSF1R选择性药物除外）无关。第25周时的客观反应率（ORR）是主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.

期刊最新文献

A new standard of care for leiomyosarcoma Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance Vorasidenib: a new hope or a false promise for patients with low-grade glioma? New clinical trials in CUP and a novel paradigm in cancer classification The age of foundation models